Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress
September 25, 2024 07:00 ET | Kymera Therapeutics, Inc.
KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease KT-621 demonstrated strong degradation of STAT6 in human...
Canon Expands Laser
Canon Expands Laser Printer Portfolio Designed to Help Create a High-Performance Small Office or At-Home Setup
September 24, 2024 09:56 ET | Canon U.S.A., Inc.
Melville, NY, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Canon U.S.A., Inc., a leader in digital imaging solutions, is proud to announce four new monochrome laser printers, enhancing its already-extensive...
Despite Projections
Despite Projections of a 2024 Adalimumab Biosimilar Boom, Humira Remains Dominant for Now, According to Spherix Global Insights
September 23, 2024 10:18 ET | Spherix Global Insights
EXTON, PA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights compiled data from their RealTime Dynamix™ services in Crohn’s Disease, Rheumatoid Arthritis, and Psoriasis, fielded in late...
Leading Dermatologic
Leading Dermatologic Associations and Skin Cancer Prevention Organizations Urge U.S. Surgeon General to Renew Skin Cancer Call to Action
September 18, 2024 12:46 ET | American Society for Dermatologic Surgery Association
Schaumburg, Ill., Sept. 18, 2024 (GLOBE NEWSWIRE) -- The American Society for Dermatologic Surgery Association (ASDSA), in conjunction with the American Academy of Dermatology Association (AAD), the...
Jason Abair headshot
Corza Medical Appoints Jason Abair as Vice President of Legal & Chief Compliance Officer
September 16, 2024 08:05 ET | Corza Medical Inc.
Corza Medical names Jason Abair as Vice President, Legal & Chief Compliance Officer.
ASDS Experts Share P
ASDS Experts Share Procedural Dermatology Techniques at Unique Hands-on Course With Innovative 3D Technology
September 16, 2024 07:00 ET | American Society for Dermatologic Surgery
Schaumburg, IL, Sept. 16, 2024 (GLOBE NEWSWIRE) -- The American Society for Dermatologic Surgery (ASDS) welcomed more than 50 dermatologic surgeons and dermatology residents to its new course, “ASDS...
DL_Logo-side-by-side.png
INVESTOR ALERT: DiCello Levitt LLP Shareholder Class Action Lawsuit Filed Against Methode Electronics, Inc. (NYSE: MEI); Investors with Losses Encouraged to Discuss Their Options with Counsel
September 13, 2024 20:06 ET | DiCello Levitt LLP
SAN DIEGO, Sept. 13, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of purchasers or acquirers of Methode Electronics, Inc. (NYSE: MEI) (“Methode” or the “Company”)...
Regeneron Logo.jpg
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
September 11, 2024 01:04 ET | Regeneron Pharmaceuticals, Inc.
Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in...
Regeneron Logo.jpg
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
September 11, 2024 00:59 ET | Regeneron Pharmaceuticals, Inc.
Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is...
The Highly Anticipat
The Highly Anticipated FDA Approvals of Galderma’s Nemolizumab and Eli Lilly’s Lebrikizumab are Expected to Shift Dermatologists’ Perceptions of the Atopic Dermatitis Market
September 09, 2024 10:20 ET | Spherix Global Insights
EXTON, PA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Since its 2017 debut as the first advanced systemic treatment for atopic dermatitis (AD), Sanofi/Regeneron’s Dupixent has dominated the US market....